Electra Therapeutics, Inc. Common stock (ETRA) — Cash Flow-to-Debt Ratio
Electra Therapeutics, Inc. Common stock (ETRA) has a Cash Flow-to-Debt Ratio of -0.47x as of December 2025, meaning its operating cash flow of $-60.48 Million could theoretically repay 0% of its total liabilities ($129.69 Million) in one year. See ETRA free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Electra Therapeutics, Inc. Common stock Cash Flow-to-Debt Ratio (2024–2025)
Historical debt coverage capacity for Electra Therapeutics, Inc. Common stock across 2 annual periods. See Electra Therapeutics, Inc. Common stock net asset quality index to measure how much of total assets are equity-financed.
Annual Cash Flow-to-Debt Ratio for Electra Therapeutics, Inc. Common stock (2024–2025)
Year-by-year debt coverage analysis for Electra Therapeutics, Inc. Common stock. For the full cash flow conversion analysis, see Electra Therapeutics, Inc. Common stock operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.47x | $-60.48 Million | $129.69 Million | ▼ -120.0% |
| 2024 | -0.21x | $-26.00 Million | $122.68 Million | — |